2026 Global: Lancet Pen Needles Market-Competitive Review (2032) report
Description
The 2026 Global: Lancet Pen Needles Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Leading players in the insulin pen needles market include Becton, Dickinson and Company (BD) in the United States; Novo Nordisk A/S in Denmark; Terumo Corporation in Japan; and Nipro Corporation in Japan. BD, a global medical technology company headquartered in Franklin Lakes, New Jersey, supplies the BD Ultra-Fine needle range used in numerous pen systems and drives global adoption through broad distribution and strict quality controls. Novo Nordisk, based in Bagsværd, Denmark, integrates its NovoFine needle line with its insulin-delivery platforms, leveraging control over both pen devices and supply components to optimize patient experience and adherence. Terumo, headquartered in Tokyo, Japan, manufactures high-precision needles and pen accessories across markets, contributing to cross-brand compatibility and ongoing innovation in needle geometry and lubrication. Nipro, with headquarters in Osaka, Japan, provides a diverse portfolio of pen needles to multiple diabetes-care brands, emphasizing scale, efficiency, and reliability. Collectively, these firms set benchmarks for sterility, needle lengths, and injection comfort, shaping the global needle ecosystem. Their coordinated advances influence patient safety, adherence, and therapeutic outcomes.
Owen Mumford Ltd, based in Oxford, United Kingdom, is recognized for injectors and diabetes-related devices, contributing to pen-needle ecosystem through device integration and safety features. Ypsomed AG, headquartered in Burgdorf, Switzerland, dominates diabetes-delivery platforms in Europe and collaborates with needle manufacturers to ensure compatibility with a wide range of pen devices. Weigao Group Co., Ltd., headquartered in Weihai, Shandong province, China, is among the largest manufacturers of injection devices and accessories, expanding the supply chain and offering cost-efficient pen-needle options for markets in Asia and beyond. By combining in-house manufacturing with external partnerships, these companies influence needle geometry options, sterility protocols, and regional supply reliability, thereby affecting patient access and device performance across diverse healthcare settings, enhancing resilience. Continued collaboration among these manufacturers and general practitioners will determine future standards for safety, comfort, and cost efficiency in insulin administration worldwide. Market dynamics will reflect regulatory harmonization and patient preference.
Gerresheimer AG, headquartered in Düsseldorf, Germany, supplies the packaging and componentry for insulin pen needles, including sterile needle assemblies and related safety devices, and plays a pivotal role in ensuring compatibility across brands through standardized packaging. B. Braun Melsungen AG, headquartered in Melsungen, Germany, maintains a presence in the diabetes-care supply chain with injection devices and accessory components that interact with pen needles, focusing on reliability, sterility, and regional manufacturing capabilities. AptarGroup, Inc., headquartered in Cranbury, New Jersey, USA, provides drug-delivery systems and precision components that influence the design and performance of pen needle ecosystems, especially within prefilled and connected-device platforms. Collectively, these companies contribute to the competitiveness of the market by advancing sterile assembly practices, material science, and distribution networks. As pen-needle technology evolves toward shorter, thinner, and smoother injection experiences, supplier relationships and quality assurance frameworks will continue to shape patient outcomes and clinician satisfaction worldwide. Across markets.
Leading players in the insulin pen needles market include Becton, Dickinson and Company (BD) in the United States; Novo Nordisk A/S in Denmark; Terumo Corporation in Japan; and Nipro Corporation in Japan. BD, a global medical technology company headquartered in Franklin Lakes, New Jersey, supplies the BD Ultra-Fine needle range used in numerous pen systems and drives global adoption through broad distribution and strict quality controls. Novo Nordisk, based in Bagsværd, Denmark, integrates its NovoFine needle line with its insulin-delivery platforms, leveraging control over both pen devices and supply components to optimize patient experience and adherence. Terumo, headquartered in Tokyo, Japan, manufactures high-precision needles and pen accessories across markets, contributing to cross-brand compatibility and ongoing innovation in needle geometry and lubrication. Nipro, with headquarters in Osaka, Japan, provides a diverse portfolio of pen needles to multiple diabetes-care brands, emphasizing scale, efficiency, and reliability. Collectively, these firms set benchmarks for sterility, needle lengths, and injection comfort, shaping the global needle ecosystem. Their coordinated advances influence patient safety, adherence, and therapeutic outcomes.
Owen Mumford Ltd, based in Oxford, United Kingdom, is recognized for injectors and diabetes-related devices, contributing to pen-needle ecosystem through device integration and safety features. Ypsomed AG, headquartered in Burgdorf, Switzerland, dominates diabetes-delivery platforms in Europe and collaborates with needle manufacturers to ensure compatibility with a wide range of pen devices. Weigao Group Co., Ltd., headquartered in Weihai, Shandong province, China, is among the largest manufacturers of injection devices and accessories, expanding the supply chain and offering cost-efficient pen-needle options for markets in Asia and beyond. By combining in-house manufacturing with external partnerships, these companies influence needle geometry options, sterility protocols, and regional supply reliability, thereby affecting patient access and device performance across diverse healthcare settings, enhancing resilience. Continued collaboration among these manufacturers and general practitioners will determine future standards for safety, comfort, and cost efficiency in insulin administration worldwide. Market dynamics will reflect regulatory harmonization and patient preference.
Gerresheimer AG, headquartered in Düsseldorf, Germany, supplies the packaging and componentry for insulin pen needles, including sterile needle assemblies and related safety devices, and plays a pivotal role in ensuring compatibility across brands through standardized packaging. B. Braun Melsungen AG, headquartered in Melsungen, Germany, maintains a presence in the diabetes-care supply chain with injection devices and accessory components that interact with pen needles, focusing on reliability, sterility, and regional manufacturing capabilities. AptarGroup, Inc., headquartered in Cranbury, New Jersey, USA, provides drug-delivery systems and precision components that influence the design and performance of pen needle ecosystems, especially within prefilled and connected-device platforms. Collectively, these companies contribute to the competitiveness of the market by advancing sterile assembly practices, material science, and distribution networks. As pen-needle technology evolves toward shorter, thinner, and smoother injection experiences, supplier relationships and quality assurance frameworks will continue to shape patient outcomes and clinician satisfaction worldwide. Across markets.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
